CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: To further examine the CAY10683 combined with IM inhibition on CML cells resistant to IM, K562-R, LAMA84-R and IM-resistant CML patients' MNC cells were subjected to 48 h of CAY10683 (0, 0.1, 0.25, 0.5 μM, CAY10683 at 0–0.5 μM had little effect on the normal CD34+ cells) and IM treatments at various doses.